Several leading advocacy groups are asking the U.S. Trade Representative not to sanction or pressure four countries — Brazil, Ukraine, South Africa, and India — if the governments grant requests from cystic fibrosis patients to sidestep or revoke patents on a pricey medicine.
The move comes after the patients and their families last month took the unusual step of petitioning their governments due to ongoing frustration that they are unable to access a Vertex Pharmaceutical treatment. They cited both the high price of the medicine, known as Trikafta, and the patenting strategies pursued in different countries around the world by the company.
The gambit largely involves the use of compulsory licenses, which lets a country grant a license to a public agency or a generic drugmaker to copy a patented medicine without the consent of the brand-name company that owns the patent. The right to take this step, which can be used to lower the cost of a prescription medicine, was memorialized in a World Trade Organization agreement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect